Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi companyKER-0193, a novel, orally bioavailable…
Delivering Governed and Secure Generative AI Agents for Life Sciences Innovation MUMBAI, India and ISELIN, N.J., July 10, 2025 /PRNewswire/…
New Research Confirms Costly Copilot Limitations, Driving Demand for Governed, Process-Centric AI Solutions That Accelerate Autonomy SAN JOSE, Calif., June…